Tucson, Arizona 85719

  • Metastatic Malignant Neoplasm in the Brain

Purpose:

This phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery. Single fraction stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Fractionated stereotactic radiosurgery delivers multiple, smaller doses of radiation therapy over time. This study may help doctors find out if fractionated stereotactic radiosurgery is better or worse than the usual approach with single fraction stereotactic radiosurgery.


Study summary:

PRIMARY OBJECTIVES: I. To ascertain if time to surgical bed failure is increased with fractionated stereotactic radiosurgery (FSRS) compared to single-fraction stereotactic radiosurgery (SSRS) in patients with resected brain metastasis. SECONDARY OBJECTIVES: I. To ascertain if there is better emotional well-being at 9 months as assessed by the Functional Assessment of Cancer Therapy-Brain (FACT-BR) in patients with resected brain metastasis undergoing FSRS compared to SSRS (Primary quality of life [QOL] objective). II. To ascertain whether there is improved overall survival in patients with resected brain metastases who undergo FSRS compared to patients who receive SSRS. III. To ascertain in patients with resected brain metastases whether there is improved overall QOL as assessed by the FACT-BR and Linear Analog Self-Assessment (LASA) in patients who receive FSRS compared to patients who receive SSRS (Secondary QOL objective). IV. To compare the functional independence in patients who receive FSRS to patients who receive SSRS. V. To tabulate and descriptively compare the post-treatment adverse events associated with the interventions, including the potential impact of immunotherapy and targeted therapy. VI. To compare rates of radiation necrosis at 12 months in patients who receive FSRS to patients who receive SSRS. VII. To evaluate if there is any difference in central nervous system (CNS) failure patterns (local, distant brain failure, local leptomeningeal disease, widespread leptomeningeal disease) in patients who receive FSRS compared to patients who receive SSRS after resection of brain metastasis. VIII. To ascertain in patients with resected brain metastases whether there is increased time to whole-brain radiotherapy (WBRT) in patients who receive FSRS compared to patients who receive SSRS. IX. To determine in long-term survivors (patients who are alive more than 12 months from time of randomization) whether there is better emotional well-being and overall QOL as assessed by the FACT-BR and LASA in patients who receive FSRS to the surgical bed compared to patients who receive SSRS (Secondary QOL objective). X. To assess for differences in CNS failure patterns (surgical, local, distant brain failure, leptomeningeal disease) as well as radiation necrosis rates as assessed by central review in patients who receive FSRS compared to patients who receive SSRS after resection of a brain metastasis. XI. To ascertain in patients with resected brain metastases whether there is improved QOL as assessed by all other total and individual FACT-BR and LASA items and subscale values in patients who receive FSRS compared to patients who receive SSRS (Exploratory QOL objective). XII. To determine in patients with resected brain metastases whether there is less cognitive progression in patients who receive FSRS to the surgical bed compared to patients who receive SSRS (Exploratory cognitive objective). OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo SSRS over 1 session. ARM II: Patients undergo FSRS over 3 or 5 daily sessions. After completion of study, patients are followed up at 30 days, at 3, 6, 9, 12, 16, and 24 months, then every 6 months until 5 years from randomization.


Criteria:

Inclusion Criteria: PRE-REGISTRATION: - Pathology from the resected brain metastasis must be consistent with a non-central nervous system primary site. Patients with or without active disease outside the nervous system are eligible (including patients with unknown primaries), as long as the pathology from the brain is consistent with a non-central nervous system primary site. - Three or fewer (i.e. 0 to 3) unresected brain metastases (as defined on the post operative magnetic resonance imaging [MRI]) at the time of screening. o Note: Dural based metastases (e.g. commonly seen in breast cancer) are eligible. - Unresected lesions must measure < 4.0 cm in maximal extent on the contrasted post-operative treatment MRI brain scan. The unresected lesions will be treated with SRS as outlined in the treatment section of the concept. o Note: The metastases size restriction does not apply to the resected brain metastasis. - One brain metastasis must be completely (gross total resection) resected =< 30 days prior to pre-registration. o NOTE: May not have had resection of more than one brain metastasis. - The resected brain metastasis must measure 2 cm or larger on the pre-operative MRI. - Resection cavity must measure < 5.0 cm in maximal extent and the resection must be complete (gross total resection) on the post-operative MRI obtained =< 30 days prior to pre-registration. - Karnofsky performance status of >= 60. - For women of childbearing potential only, a negative urine or serum pregnancy test done =< 7 days prior to pre-registration is required. - Men and women of childbearing potential must be willing to employ adequate contraception throughout the study and for men for up to 3 months after completing treatment. - A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). - Ability to complete an MRI of the head with contrast. - The brain metastasis must be located > 5 mm of the optic chiasm; the brain metastasis must be located outside the brainstem (i.e. not inside the brainstem). - Must not have any prior whole brain radiation therapy. - Past radiosurgery to other lesions is allowed. o NOTE: The surgically resected lesion cannot be the same location treated in the past with radiosurgery (i.e. repeat radiosurgery to the same location/lesion is not allowed on this protocol). - May not have primary germ cell tumor, small cell carcinoma, or lymphoma. - No evidence of leptomeningeal metastasis (LMD). o NOTE: For the purposes of exclusion, LMD is a clinical diagnosis, defined as positive cerebrospinal fluid (CSF) cytology and/or equivocal radiologic or clinical evidence of leptomeningeal involvement. Patients with leptomeningeal symptoms in the setting of leptomeningeal enhancement by imaging (MRI) would be considered to have LMD even in the absence of positive CSF cytology, unless a parenchymal lesion can adequately explain the neurologic symptoms and/or signs. In contrast, an asymptomatic or minimally symptomatic patient with mild or nonspecific leptomeningeal enhancement (MRI) would not be considered to have LMD. In that patient, CSF sampling is not required to formally exclude LMD, but can be performed at the investigator's discretion based on level of clinical suspicion. - Must be fluent in English, Spanish, or French. REGISTRATION: • Completion of all baseline electronic patient-reported outcome (ePRO) quality of life measures (or booklet quality of life measures) and Montreal Cognitive Assessment (MoCA).


Study is Available At:


Original ID:

A071801


NCT ID:

NCT04114981


Secondary ID:

NCI-2019-02394


Study Acronym:


Brief Title:

Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Dis


Official Title:

Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease


Overall Status:

Recruiting


Study Phase:

Phase 3


Genders:

N/A


Minimum Age:

18 Years


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Alliance for Clinical Trials in Oncology


Oversight Authority:

There was an error processing this request


Reasons Why Stopped:


Study Type:

Interventional


Study Design:


Number of Arms:

2


Number of Groups:

0


Total Enrollment:

208


Enrollment Type:

Anticipated


Overall Contact Information

Official Name:Paul D. Brown, MD
Study Chair
Mayo Clinic
Primary Contact:Paul D. Brown, MD
507-284-3551
brown.paul@mayo.edu

Study Dates

Start Date:October 11, 2019
Completion Date:March 2028
Completion Type:Anticipated
Primary Completion Date:March 2025
Primary Completion Type:Anticipated
Verification Date:April 2022
Last Changed Date:April 18, 2022
First Received Date:October 2, 2019

Study Outcomes

Outcome Type:Primary Outcome
Measure:Surgical bed recurrence-free survival (SB-RFS)
Time Frame:From the time of randomization up to 2 years post radiation
Safety Issues:False
Description:Surgical bed control is defined as the absence of new nodular contrast enhancement in the surgical bed. In other words, a surgical bed recurrence-free survival (SB-RFS) event is defined as radiographic evidence of a new contrast-enhancing lesion (specific
Outcome Type:Secondary Outcome
Measure:Change in Functional Assessment of Cancer Therapy-Brain (FACT-BR) Emotional sub-scale score
Time Frame:At 9 months
Safety Issues:False
Description:The average change from baseline to 9 months in the Functional Assessment of Cancer Therapy-Brain (FACT-BR) Emotional sub-scale will be compared between randomization arms.
Outcome Type:Secondary Outcome
Measure:Functional Assessment of Cancer Therapy-Brain (FACT-BR) total score
Time Frame:At 9 months
Safety Issues:False
Description:The average change from baseline to 9 months in the Functional Assessment of Cancer Therapy-Brain (FACT-BR) total score will be compared between randomization arms.
Outcome Type:Secondary Outcome
Measure:Linear Analog Self-Assessment (LASA) overall quality of life
Time Frame:At 9 months
Safety Issues:False
Description:The average change from baseline to 9 months in the Linear Analog Self-Assessment (LASA) overall total score will be compared between randomization arms.
Outcome Type:Secondary Outcome
Measure:Functional Assessment of Cancer Therapy-Brain (FACT-BR) Emotional sub-scale score for long-term survivors
Time Frame:At 12 months
Safety Issues:False
Description:Long-term survivors defined as patients who are alive more than 12 months from time of randomization. The average change from baseline to 12 months in the Functional Assessment of Cancer Therapy-Brain (FACT-BR) Emotional sub-scale for the long-term surviv
Outcome Type:Secondary Outcome
Measure:Functional Assessment of Cancer Therapy-Brain (FACT-BR) total score for long-term survivors
Time Frame:At 12 months
Safety Issues:False
Description:Long-term survivors defined as patients who are alive more than 12 months from time of randomization. The average change from baseline to 12 months in the Functional Assessment of Cancer Therapy-Brain (FACT-BR) total score for the long-term survivors will
Outcome Type:Secondary Outcome
Measure:Linear Analog Self-Assessment (LASA) overall quality of life for long-term survivors
Time Frame:At 12 months
Safety Issues:False
Description:Long-term survivors defined as patients who are alive more than 12 months from time of randomization. The average change from baseline to 9 months in the Linear Analog Self-Assessment (LASA) overall total score for the long-term survivors will be compared
Outcome Type:Secondary Outcome
Measure:Karnofsky Performance Status (KPS)
Time Frame:Up to 24 months
Safety Issues:False
Description:The duration of Karnofsky Performance Status (KPS) functional independence will be the time to when the KPS scores per patient decrease below their baseline level and will be compared between treatment arms by the logrank test. Median durations of KPS fun
Outcome Type:Secondary Outcome
Measure:Barthel Activities of Daily Living (ADL) Index
Time Frame:Up to 24 months
Safety Issues:False
Description:The duration of Barthel Activities of Daily Living (ADL) functional independence will be the time to when the ADL scores per patient decrease below their baseline level and will be compared between treatment arms by the logrank test. Median durations of A
Outcome Type:Secondary Outcome
Measure:Karnofsky Performance Status (KPS) for long-term survivors
Time Frame:Up to 24 months
Safety Issues:False
Description:Long-term survivors defined as patients who are alive more than 12 months from time of randomization. The duration of Karnofsky Performance Status (KPS) functional independence will be the time to when the KPS scores per patient decrease below their basel
Outcome Type:Secondary Outcome
Measure:Barthel Activities of Daily Living (ADL) Index for long-term survivors
Time Frame:Up to 24 months
Safety Issues:False
Description:Long-term survivors defined as patients who are alive more than 12 months from time of randomization. The duration of Barthel Activities of Daily Living (ADL) functional independence will be the time to when the ADL scores per patient decrease below their
Outcome Type:Secondary Outcome
Measure:Overall survival
Time Frame:Up to 5 years
Safety Issues:False
Description:Overall survival time will be compared between the treatment arms using a stratified log-rank test. If the proportional hazards assumption is violated, a restricted means analysis will be used to compare overall survival between the two treatment arms. Me
Outcome Type:Secondary Outcome
Measure:Incidence of adverse events
Time Frame:Up to 24 months
Safety Issues:False
Description:The Common Terminology Criteria for Adverse Events version 5.0 will be used. The proportion of patients experiencing any adverse event will be compared between the two treatment arms using a chi-square (or Fisher's exact test, if more appropriate).
Outcome Type:Secondary Outcome
Measure:Proportion of patients with radiation necrosis
Time Frame:At 24 months
Safety Issues:False
Description:The proportion of patients with radiation necrosis within 24 months from of starting treatment will be compared between the treatment arms with a chi-square test (or Fisher's exact test if more appropriate).
Outcome Type:Secondary Outcome
Measure:Time until whole-brain radiotherapy (WBRT) due to any reason (e.g. surgical bed recurrence, recurrence/progression at another central nervous system [CNS] site)
Time Frame:Up to 24 months
Safety Issues:False
Description:Time until whole-brain radiotherapy (WBRT) will be compared between the treatment arms using a stratified log-rank test. Median time until WBRT per treatment arms will be reported.

Study Interventions

Intervention Type:Radiation
Name:Single Fraction Stereotactic Radiosurgery
Description:Undergo SSRS
Arm Name:Arm I (SSRS)
Other Name:Stereotactic Radiosurgery
Intervention Type:Radiation
Name:Fractionated Stereotactic Radiosurgery
Description:Undergo FSRS
Arm Name:Arm II (FSRS)
Other Name:Stereotactic Radiosurgery
Intervention Type:Procedure
Name:Quality-of-Life Assessment
Description:Ancillary studies
Arm Name:Arm I (SSRS)
Intervention Type:Other
Name:Questionnaire Administration
Description:Ancillary studies
Arm Name:Arm I (SSRS)

Study Arms

Study Arm Type:Active Comparator
Arm Name:Arm I (SSRS)
Description:Patients undergo SSRS over 1 session.
Study Arm Type:Experimental
Arm Name:Arm II (FSRS)
Description:Patients undergo FSRS over 3 or 5 daily sessions.

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Alliance for Clinical Trials in Oncology
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: February 02, 2023

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


If you would like to be contacted by the clinical trial representative please fill out the form below.